MedPath

Rapport Therapeutics Gains Buy Recommendation Based on RAP Platform and RAP-219 Potential

• Rapport Therapeutics receives a Buy rating from JonesTrading, driven by its innovative RAP platform targeting central nervous system disorders. • RAP-219, Rapport's lead candidate, shows promise for treating epilepsy, pain, and bipolar disorder by targeting TARPγ8, with Phase II trials planned for 2025. • Integration of NeuroPace's RNS device could enhance clinical proof of concept for RAP-219, improving patient recruitment and trial outcomes. • Strategic focus on selective targeting aims to minimize side effects, potentially positioning RAP-219 as a best-in-class treatment.

Rapport Therapeutics, Inc. (RAPP) has garnered a new Buy rating from JonesTrading analyst Justin Walsh, citing the company's innovative approach to treating central nervous system (CNS) disorders. The recommendation highlights the potential of Rapport's receptor associated protein (RAP) platform and its lead product candidate, RAP-219.

RAP-219: A Promising Candidate

RAP-219 is designed to target TARPγ8, a protein linked to conditions such as epilepsy, pain, and bipolar disorder. Rapport Therapeutics anticipates initiating Phase II trials for each of these indications by 2025, which could significantly advance the clinical validation of RAP-219. The drug's mechanism of action involves inhibiting TARPγ8-containing AMPARs with picomolar affinity, offering a potentially highly selective approach to treating these disorders.

Strategic Advantages and Clinical Validation

The potential integration of the RNS device from NeuroPace is expected to bolster the clinical proof of concept for RAP-219. This integration could provide a unique advantage in patient recruitment and improve trial outcomes. Furthermore, Rapport's strategic emphasis on selective targeting aims to minimize side effects, enhancing the potential for RAP-219 to achieve best-in-class status in its therapeutic area.

Analyst Perspective

Justin Walsh's Buy rating is based on the anticipation of substantial revenue generation and the possibility of RAP-219 moving to earlier lines of treatment. According to TipRanks, Walsh is an analyst specializing in the Healthcare sector, with coverage including companies like Achieve Life Sciences, Lantheus, and Monopar Therapeutics Inc.

Rapport Therapeutics' Pipeline

In addition to RAP-219, Rapport Therapeutics is also developing RAP-199, another TARPγ8-targeted molecule with differentiated chemical and pharmacokinetic properties. The company's pipeline includes nicotinic acetylcholine receptor (nAChR) programs, such as α6 nAChR for chronic pain and α9α10 nAChR for hearing disorders, demonstrating a broad focus on addressing unmet needs in CNS disorders.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Rapport Therapeutics' RAP-219 Shows Promise in Phase 1 Trials for CNS Disorders

Rapport Therapeutics' RAP-219 achieved target receptor occupancy within five days, supporting its potential for treating CNS disorders.
The Phase 1 trials demonstrated a favorable tolerability profile for RAP-219, with no serious adverse events reported in healthy volunteers.

Palvella Therapeutics Gains Analyst Attention with QTORIN Rapamycin Development for Rare Skin Diseases

Palvella Therapeutics is developing QTORIN 3.9% rapamycin anhydrous gel for rare genetic skin diseases, addressing unmet needs.
Phase 3 trial data for microcystic lymphatic malformations (mLMs) is expected in early 2026, with potential market launch in 2027.

Protagonist Therapeutics' Rusfertide Shows Promise in Polycythemia Vera Treatment

Protagonist Therapeutics' rusfertide demonstrates durable hematocrit control in Phase 3 trials for polycythemia vera, reducing the need for phlebotomy.
Strategic partnerships, including collaboration with Johnson & Johnson on JNJ-2113, expand Protagonist's pipeline into psoriasis and ulcerative colitis treatments.

Rapport Therapeutics Provides Update on RAP-219 Clinical Trials and Financial Results

Rapport Therapeutics is advancing RAP-219, a precision medicine for CNS disorders, with Phase 2a trial in focal epilepsy on track for mid-2025 data.
A clinical hold was placed on the RAP-219 trial for diabetic peripheral neuropathic pain (DPNP) by the FDA, pending protocol amendments.

FDA Halts Rapport Therapeutics' RAP-219 Trial for Diabetic Neuropathic Pain

The FDA has placed a clinical hold on Rapport Therapeutics' IND application for RAP-219, an investigational therapy for diabetic peripheral neuropathic pain (DPNP).
The agency is requesting additional information on the trial's protocol design, which Rapport Therapeutics believes it can address promptly.

Rapport Therapeutics Provides Update on RAP-219 Clinical Programs and Financial Status

Rapport Therapeutics is advancing RAP-219 in Phase 2a trials for focal epilepsy, with topline data expected in mid-2025, showing commitment to CNS disorder treatments.
The FDA placed a clinical hold on Rapport's RAP-219 trial for diabetic peripheral neuropathic pain, prompting the company to address protocol feedback.

Rapport Therapeutics Advances RAP-219 Clinical Trials for CNS Disorders

Rapport Therapeutics is progressing with Phase 2a trial of RAP-219 in focal epilepsy, with topline data expected in mid-2025.
Multiple Ascending Dose (MAD-2) and PET trials of RAP-219 are ongoing, with topline results anticipated in Q1 2025.

Roche's Itovebi Approval Boosts Relay Therapeutics Following Positive Trial Data

The FDA approved Roche's Itovebi (inavolisib) in combination with Ibrance and Faslodex for HR+, HER2- advanced or metastatic breast cancer with PIK3CA mutation.
The approval was based on the Phase 3 INAVO120 trial, which showed a 57% reduction in disease progression or death compared to Ibrance and Faslodex alone.

Praxis Precision Medicines Sees Positive Analyst Outlook Following Pipeline Progress

Praxis Precision Medicines receives reiterated Buy rating and $120 price target from H.C. Wainwright after positive Phase 2 data for relutrigine and favorable reviews for PRAX-628.
The company's advancements in epilepsy portfolio, including pivotal readout for PRAX-628 and Essential3 trial progress, position it for significant growth in the next year.

Vor Biopharma Announces Positive Data and New CD45 ADC Program, Analysts See Significant Upside

Vor Biopharma reported updated Phase 1/2 VBP101 study results showing promising relapse-free survival data in AML/MDS patients, exceeding historical benchmarks.
Initial PK data for VCAR33ALLO demonstrated in vivo expansion at the lowest dose, with dose escalation planned, indicating potential efficacy.

Reference News

[1]
Promising Growth and Innovation Drive Buy Recommendation for Rapport Therapeutics, Inc.
markets.businessinsider.com · Oct 18, 2024

JonesTrading analyst Justin Walsh initiates Buy rating on Rapport Therapeutics, Inc. (RAPP) due to its innovative RAP pl...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy